Oral dosing of GLP-1 compounds

US12514822B2 · 01/06/2026

FIG. 1 · Sheet 1

The present invention relates to improved uses of glucagon-like peptide 1 (GLP-1) peptides in oral therapy.

Full text

3 sections

Abstract The present invention relates to improved uses of glucagon-like peptide 1 (GLP-1) peptides in oral therapy.

Official name

Oral dosing of GLP-1 compounds

Publication number

US12514822B2

Inventor / creator

Flemming S. Nielsen

Assignee / owner

Novo Nordisk A/S

Filing

04/28/2025

Publication

01/06/2026

Expiry

04/28/2045

Status

ACTIVE

No articles yet — metadata is still available from the registry.

0 replies · cite patents with ^

Join the discussion

No comments yet.